Marketing behavioral health: Implications of evidence assessments for behavioral health care in the United States

International Journal of Mental Health

Volumn 35, Issue 2, 2006, Pages 6-20

  Leff, Stephen ^a,b   Conley, Jeremy ^b   Hennessy, Kevin ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Human Services Research Institute   (United States)

^c SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

Commercialization; Evidence based practice; Government policy; International harmonization; Intervention science

Indexed keywords

EID: 33845507310     PISSN: 00207411     EISSN: None     Source Type: Journal    
DOI: 10.2753/IMH0020-7411350201     Document Type: Review

References (49)

1. Australasian Cochrane Collaboration (2006, February) Mission statement of the Australasian Cochrane Centre. Available at www.cochrane.org.au/about_us/ about_us.htm#Mission/, accessed July 21, 2006.
2. Canadian Institute of Health Research (2006) Investing in Canada's future: CIHR's blueprint for health research and innovation. Ottawa. Available at www.cihr-irsc.gc.ca/e/20266.html, accessed April 17, 2006.
3. Fowler, G. (2001) Evidence-based practice: Tools and techniques. In A.M. Roche & J. McDonald (Eds.), Systems, settings, people: Workforce development challenges for the alcohol and other drugs field (pp. 93-107). Adelaide, Australia: National Centre for Education and Training on Addiction.
4. Lehtinen, V. (2004, December) Action for mental health activities co-funded from European community public health programmes 1997-2004. Report prepared for the European Commission, Health and Consumer Protection Directorate-General. Luxembourg: European Commission. Available at ec.europa.eu/comm/health/ph_determinants/life_style/mental/docs/ action_1997_2004_en.pdf, accessed April 14, 2006.
5. New Zealand Guidelines Group (2006, April) Mission and values of the New Zealand Guidelines Group. Wellington. Available at www.nzgg.org.nz/index.cfm? fuseaction=about&fusesubaction=docs&documentID=77/, accessed April 16, 2006.
6. Lipsey, M.W. (2005) The challenge of interpreting research for use by practitioners: Comments on the latest products from the task force on community preventive services. American Journal of Preventive Medicine, 25(2S1), 1-3.
7. Blue Ribbon Task Force on NIDA Health Services Research (2004) Report of the Blue Ribbon Task Force on Health Services Research at the National Institute of Drug Abuse. San Francisco: University of California.
8. Institute of Medicine (2001) Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academy Press.
9. President's New Freedom Commission on Mental Health (2003) Achieving the promise: Transforming mental health care in America. Rockville, MD.
10. U.S. Department of Health and Human Services (1999) Mental health: A report of the Surgeon General. Rockville. MD.
11. Leff, H.S. (2005) Evidence in intervention science. In R.E. Drake, M.R. Merrens, & D.W. Lynde (Eds.). Evidenced-based mental health practice: A textbook. New York: Norton.
12. Ziman, J. (2000) Real science: What it is and what it means. Cambridge: Cambridge University Press.
13. Krimsky, S. (2003) Science in the private interest: Has the lure of profits corrupted biomedical research? Lanham, MD: Rowman & Littlefield.
14. Chesbrough, H. (2003) Open innovation: The new imperative for creating and profiting for technology. Boston: Harvard Business School Press.
15. Hilts, P. J. (2003) Protecting America's health: The FDA, business, and one hundred years of regulation. New York: Knopf.
16. Leff, H.S.; Conley, J.; & Elmore, S. (2005) Making the grade: A review and comparison of selected evidence grading systems. Report prepared for the National Research Council. National Academy of Sciences. Cambridge, MA: Human Services Research Institute.
17. Leff, H.S., & Conley, J. (in press) Desired attributes of evidence assessments for evidence-based practices. Administration and Policy in Mental Health and Mental Health Services Research.
18. Bok, D. (2003) Universities in the marketplace: The commercialization of higher education. Princeton: Princeton University Press.
19. Institute of Medicine (1998) Scientific opportunities and public needs: Improving priority setting and public input at the National Institutes of Health. Washington, DC: National Academy Press.
20. Alcohol. Drug Abuse, and Mental Health Reorganization Act of 1992. Pub. L. No. 102-321 § 106 Stat. 394 (1992).
21. Klebe, E.R., & Judge, K.M. (1993) The alcohol, drug abuse, and mental health administration (ADAMHA) reorganization act of 1992 (CRS 93-597 EPW). Washington. DC: Penny Hill Press.
22. Insel, T.R. (2003) Minutes of the 203rd meeting. In Proceedings of the National Advisory Mental Health Council. Bethesda, MD: National Institute of Mental Health. Available at www.nimh.nih.gov/council/cnclmins_5-03.pdf, accessed March 12, 2005.
23. Substance Abuse and Mental Health Service Administration (2006, March 14) Changes to the National Registry of Evidence-Based Programs and Practices (NREPP). 71 Fed. Reg. 1.3, 132.
24. Healy, D. (2002) The creation of psychopharmacology. Cambridge: Harvard University Press.
25. U.S. Senate. (1991) A bill to amend Title V of the Public Health Service Act to revise and extend certain programs, to restructure the Alcohol. Drug Abuse and Mental Health Administration, and for other purposes (Senate Report 102-131). Washington DC: Government Printing Office.
26. Sharfstein, S. (2005) The loss of federal support for multisite demonstrations. Psychiatric Services, 56(10), 1185.
27. Arons, B.S. (2005) Recovering the momentum for federal support of multisite demonstrations. Psychiatric Services, 56(12), 1621.
28. Healy, D. (2004) Let them eat Prozac: The unhealthy relationship between the pharmaceutical industry and depression. New York: New York University Press.
29. Schoenwald, S.; Brown, T.L.; & Henggeler, S.W. (2000) Insider multisystemic therapy: Therapist, supervisory, and program practices. Journal of Emotional and Behavioral Disorders, 8(2), 113-128.
30. Healy, D. (1997) The antidepressant era. Cambridge: Harvard University Press.
31. Chan, A.; Hrobajartsson, A.; Haahr, M.T.; Gotzsche, P.C.; & Altman, D.G. (2004) Empirical evidence for selective reporting of outcomes in randomized trials. Journal of the American Medical Association, 29/(20), 2457-2465.
32. Reuters Health Information (2004) Glaxo, pressured by Spitzer, publishes Paxil data. Available from Medscape database, www.medscape.com, accessed June 22, 2004.
33. Reuters Health Information (2004) Medical journals may force disclosure of bad trials. Available from Medscape database, www.medscape.com, accessed June 22, 2004.
34. Reuters Health Information (2004) TV ad for GlaxoSmithKline's Paxil too broad-FDA. Available from Medscape database, www.medscape.com, accessed June 22, 2004.
35. Rodrigues, R.J. (2000) Information systems: The key to evidence-based health practice. Bulletin of the World Health Organization, 78(11), 1344-1351.
36. Sim, I. (1997) Trial banks: An informatics foundation for evidence-based medicine. Ph.D. dissertation, Stanford University.
37. Kramer, T.A.M. (2004) Psychopharmacology in the New York Times. Medscape General Medicine, 6(2). Available at www.medscape.com/viewarticle/480613/. accessed June 20, 2004.
38. Flay, B.R.; Biglan, A.; Boruch, R.F.; et al. (2005) Standards of evidence: Criteria for efficacy, effectiveness and dissemination. Prevention Science, 6(3), 151.
39. Lyons, J.S., & McCulloch, J.R. (2006) Monitoring and managing outcomes in residential treatment: Practice-based evidence in search of evidence-based practice. Journal of the American Academy of Child and Adolescent Psychiatry, 45(2), 247.
40. Trauer, T.; Callaly, T.; & Coombs, T. (2003) Routine outcome measurement by mental health-care providers. Lancet 361(9363), 1137.
41. Kitcher, P. (2001) Science, truth, and democracy. Oxford: Oxford University Press.
42. Hayashi, Y. (2003) Impact of the International Conference on Harmonisation in Asia. Drug Information Journal, 37(Suppl.), 129-137.
43. International Conference on Harmonisation (2006) Structure of the International Conference on Harmonisation. Geneva. Available at www.ich.org/cache/compo/276-254-l.html, accessed April 17, 2006.
44. International Conference on Harmonization (1998, September 16) Guidance on statistical principles for clinical trials; availability, 63 Fed. Reg. 49, 583. Geneva.
45. Ono, S.; Kato, O.; Tsutani, K.; & Kodama, Y. (2004) Utilisation of foreign clinical data in Japanese new drug approval review: On what basis did the regulatory agency accept them? International Journal of Pharmaceutical Medicine, 18(3), 159-165.
46. National Health Service (2006) Best treatments for mental health. London. Available at www.besttreatments.co.uk/btuk/health-topic/mental-health.jsp, accessed April 25, 2006.
47. Cochrane Collaboration (2004, March) Cochrane reviewers handbook 4.2.2. Oxford. Available at www.cochrane.org/resources/handbook/index.htm, accessed June 1, 2004.
48. Cochrane Collaboration (2006) Cochrane review index. Oxford. Available at www.cochrane.org/reviews/en/index.html, accessed May 11, 2006.
49. World Health Organization (2001) Management of substance dependence review series: Systematic review of treatment for amphetamine-related disorders. Geneva. Available at http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.5.pdf. accessed March 3, 2003.